Fresenius Medical Care reported a strong start to fiscal year 2025, with first-quarter revenue increasing by 3% to EUR 4,881 million, or 5% organically. Operating income significantly increased by 35% to EUR 331 million, or 13% excluding special items, reaching a margin of 9.4%.
Both Care Delivery and Care Enablement segments contributed to organic revenue growth, with Care Enablement expanding its operating income margin into its target band for the first time. Despite a severe flu season impacting U.S. same-market treatment growth, patient referrals increased, leading to an expectation of accelerating U.S. same-market treatment growth to above 0.5% for the full year.
The company confirmed its full-year 2025 outlook, anticipating positive to low-single digit percentage revenue growth and high-teens to high-twenties percentage operating income growth, excluding special items. The FME25 transformation program continued its momentum, delivering EUR 68 million in additional sustainable savings during the quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.